EU approves RoActemra (Roche) for polyarticular Juvenile Idiopathic Arthritis
The EMA has approved RoActemra (tocilizumab), from Roche, to treat children with Polyarticular Juvenile Idiopathic Arthritis (PJIA), a rare, chronic and debilitating form of childhood Arthritis. The medicine can be used to treat patients two years of age and older who have not responded adequately to treatment with methotrexate (MTX). RoActemra can be used alone or in combination with MTX.
This is the second pediatric indication for RoActemra and follows its 2011 EMA approval for systemic Juvenile Idiopathic Arthritis. The approval is based on the Phase III CHERISH study data that showed patients treated with RoActemra experienced clinically meaningful improvement in signs and symptoms of PJIA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.